Efficacy and safety of the human anti-IL-1β monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, Phase II, dose-finding study.

BMC Musculoskelet Disord 2011 Jul 7;12:153. Epub 2011 Jul 7.

Department of Internal Medicine II, Schlosspark-Klinik Teaching Hospital of the Charité, University Medicine Berlin, Heubnerweg, Berlin 14059, Germany.

Background: Canakinumab is a fully human anti-interleukin IL-1beta monoclonal antibody, being investigated for the treatment of rheumatoid arthritis (RA). This multicenter, phase II, randomized, double-blind, placebo-controlled, parallel-group, dose-finding study investigated the efficacy and safety of canakinumab in patients with active RA despite ongoing therapy at stable doses of methotrexate.

Methods: Patients were randomized to receive one of four regimens, in addition to methotrexate, for 12 weeks: canakinumab 150 mg subcutaneously (SC) every 4 weeks (q4wk), canakinumab 300 mg SC (2 injections of 150 mg SC) every 2 weeks, a 600 mg intravenous loading dose of canakinumab followed by 300 mg SC every 2 weeks', or placebo SC every 2 weeks.

Results: Among 274 patients with evaluable efficacy data, the percentage of responders according to American College of Rheumatology 50 criteria (the primary endpoint, based on a 28-joint count) was significantly higher with canakinumab 150 mg SC q4wk than with placebo (26.5% vs. 11.4%, respectively; p = 0.028). Compared to placebo, this dosage of canakinumab was also associated with significantly more favorable responses at week 12 with respect to secondary endpoints including the Disease Activity Score 28, scores on the Health Assessment Questionnaire and Functional Assessment of Chronic Illness Therapy-Fatigue, swollen 28-joint count, and patient's and physician's global assessments of disease activity. No safety concerns were raised with canakinumab therapy, particularly with regard to infections. Few injection-site reactions occurred.

Conclusion: The addition of canakinumab 150 mg SC q4wk improves therapeutic responses among patients who have active RA despite stable treatment with methotrexate.

Trial Registration: (ClinicalTrials.gov identifier: NCT00784628).

Download full-text PDF

Source
http://bmcmusculoskeletdisord.biomedcentral.com/articles/10.
Publisher Site
http://dx.doi.org/10.1186/1471-2474-12-153DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3152943PMC
July 2011
59 Reads
1.898 Impact Factor

Publication Analysis

Top Keywords

canakinumab 150
12
canakinumab
10
rheumatoid arthritis
8
disease activity
8
active despite
8
patients active
8
28-joint count
8
150 q4wk
8
monoclonal antibody
8
dose-finding study
8
canakinumab 300
8
efficacy safety
8
q4wk canakinumab
4
percentage responders
4
therapy regard
4
data percentage
4
evaluable efficacy
4
efficacy data
4
responders american
4
regard infections
4

References

(Supplied by CrossRef)

DM Lee et al.
Lancet 2001

JM Dayer et al.
Rheumatology (Oxford) 2003

PP Tak et al.
Arthritis Rheum 2000

H Lettesjö et al.
Scand J Immunol 1998

HJ Lachmann et al.
N Engl J Med 2009

N Ruperto et al.
Arthritis Rheum 2009

N Schlesinger et al.
Arthritis Rheum 2010

R Alten et al.
Arthritis Res Ther 2008

FC Arnett et al.
Arthritis Rheum 1988

Similar Publications